Sign in to view content

Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2

John A. Wells, MD, FACS

Video
Published 2024

Related

Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor-Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Annual Meeting Talks
2024
Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2024

Category: Instrumentation and Devices

See more